{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-002610","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.578681+00:00","generated_at":"2026-05-27T04:01:13.667981+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NRx Pharma secures $27M financing for subsidiary Hope Therapeutics clinic rollup","bullets":["Private placement of 732,600 shares at $2.73/share for $2M immediate funding.","Investor committed to $25M in Hope Series A Preferred convertible into 1/3 equity, 15% dividend, non-callable for 2 years.","First $6.75M tranche of Hope investment due by Feb 7, 2025; remaining $18.25M by Apr 1, 2025.","Funds to acquire Kadima Neuropsychiatry and start nationwide interventional psychiatry clinic rollup.","Company anticipates pro-forma revenue of ~$100M by end of 2025 using bank leverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-002610","json":"https://secwatch.observer/filing/0001437749-25-002610.json","markdown":"https://secwatch.observer/filing/0001437749-25-002610.md","text":"https://secwatch.observer/filing/0001437749-25-002610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/0001437749-25-002610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925002610/nrxp20250203_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T04:01:13.667981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}